Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

  Claudia Pasqualini AuthorId : 11325673
Author ORCID : https://orcid.org/0000-0002-1113-2792

  Jonathan Rubino AuthorId : 12535405
Author ORCID : https://orcid.org/0000-0002-2980-0779

  Caroline Brard AuthorId : 11675217
Author ORCID : https://orcid.org/0000-0002-0196-4157

  Lydie Cassard AuthorId : 1397521
Author ORCID : https://orcid.org/0000-0001-8373-041X

  Nicolas André ¹ AuthorId : 857684
Author

  Windy Rondof AuthorId : 11675781
Author

  Jean-Yves Scoazec AuthorId : 163878
Author ORCID : https://orcid.org/0000-0003-1604-6823

  Antonin Marchais AuthorId : 514093
Author

  Souad Nebchi AuthorId : 12535406
Author

  Lisa Boselli AuthorId : 1636228
Author ORCID : https://orcid.org/0000-0003-0072-2428

  Jonathan Grivel AuthorId : 11350468
Author

  Isabelle Aerts AuthorId : 1307563
Author

  Estelle Thebaud AuthorId : 11381296
Author

  Xavier Paoletti AuthorId : 11769330
Author

  Véronique Minard-Colin AuthorId : 463146
Author

  Gilles Vassal AuthorId : 149152
Author

  Birgit Geoerger AuthorId : 1560919
Author